Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer

Sofia Palacio, Arturo Loaiza-Bonilla, Muaiad Kittaneh, Christos Kyriakopoulos, Roberto E. Ochoa, Mauricio Escobar, Belisario Arango, Maria H Restrepo, Jaime R Merchan, Caio M S Rocha Lima, Peter Hosein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: There is no standard chemotherapy regimen that is universally accepted for the treatment of advanced gastric cancer. Trastuzumab added to chemotherapy improves survival in patients with metastatic human epidermal growth factor receptor-2 (Her2/neu)-overexpressing gastric cancer. Data are lacking for the combination of trastuzumab with other chemotherapy regimens, apart from the cisplatin/fluorouracil backbone used in the pivotal TOGA trial. Patients and Methods: In this retrospective analysis, we included patients with gastric cancer with HER2 overexpression who received trastuzumab in addition to their first-line chemotherapy, with or without trastuzumab maintenance therapy. The end-points were response and tolerance to treatment. Results: We identified seven patients who met the search criteria; six had metastatic disease and one had locally advanced unresectable disease. Four patients received epirubicin/oxaliplatin/capecitabine/trastuzumab, and the others had non-anthracycline-based chemotherapy with trastuzumab. All patients had radiological responses to treatment - one had a complete response and six had partial responses. Among the four patients who received anthracycline-based chemotherapy with trastuzumab, there was a transient decline in cardiac ejection fraction in three, but all resolved without sequelae. All patients received a period of chemotherapy induction followed by trastuzumab monotherapy for maintenance. The median progression-free survival was 14.6 months and median overall survival was 16.4 months. Conclusion: Trastuzumab is an important agent for the treatment of HER2-overexpressing gastric cancer. We recorded an acceptable safety and efficacy profile in this small cohort treated with anthracycline-based chemotherapy with trastuzumab followed by trastuzumab maintenance.

Original languageEnglish
Pages (from-to)301-306
Number of pages6
JournalAnticancer Research
Volume34
Issue number1
StatePublished - Jan 1 2014

Fingerprint

Anthracyclines
Stomach Neoplasms
Maintenance
Drug Therapy
oxaliplatin
Trastuzumab
Therapeutics
Epirubicin
Induction Chemotherapy
Survival
Fluorouracil
Cisplatin
Disease-Free Survival
Safety

Keywords

  • Chemotherapy
  • Gastric cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer. / Palacio, Sofia; Loaiza-Bonilla, Arturo; Kittaneh, Muaiad; Kyriakopoulos, Christos; Ochoa, Roberto E.; Escobar, Mauricio; Arango, Belisario; Restrepo, Maria H; Merchan, Jaime R; Lima, Caio M S Rocha; Hosein, Peter.

In: Anticancer Research, Vol. 34, No. 1, 01.01.2014, p. 301-306.

Research output: Contribution to journalArticle

Palacio, S, Loaiza-Bonilla, A, Kittaneh, M, Kyriakopoulos, C, Ochoa, RE, Escobar, M, Arango, B, Restrepo, MH, Merchan, JR, Lima, CMSR & Hosein, P 2014, 'Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer', Anticancer Research, vol. 34, no. 1, pp. 301-306.
Palacio, Sofia ; Loaiza-Bonilla, Arturo ; Kittaneh, Muaiad ; Kyriakopoulos, Christos ; Ochoa, Roberto E. ; Escobar, Mauricio ; Arango, Belisario ; Restrepo, Maria H ; Merchan, Jaime R ; Lima, Caio M S Rocha ; Hosein, Peter. / Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 1. pp. 301-306.
@article{bd365148433e41cd8fc7e2ebc33ff36a,
title = "Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer",
abstract = "Background: There is no standard chemotherapy regimen that is universally accepted for the treatment of advanced gastric cancer. Trastuzumab added to chemotherapy improves survival in patients with metastatic human epidermal growth factor receptor-2 (Her2/neu)-overexpressing gastric cancer. Data are lacking for the combination of trastuzumab with other chemotherapy regimens, apart from the cisplatin/fluorouracil backbone used in the pivotal TOGA trial. Patients and Methods: In this retrospective analysis, we included patients with gastric cancer with HER2 overexpression who received trastuzumab in addition to their first-line chemotherapy, with or without trastuzumab maintenance therapy. The end-points were response and tolerance to treatment. Results: We identified seven patients who met the search criteria; six had metastatic disease and one had locally advanced unresectable disease. Four patients received epirubicin/oxaliplatin/capecitabine/trastuzumab, and the others had non-anthracycline-based chemotherapy with trastuzumab. All patients had radiological responses to treatment - one had a complete response and six had partial responses. Among the four patients who received anthracycline-based chemotherapy with trastuzumab, there was a transient decline in cardiac ejection fraction in three, but all resolved without sequelae. All patients received a period of chemotherapy induction followed by trastuzumab monotherapy for maintenance. The median progression-free survival was 14.6 months and median overall survival was 16.4 months. Conclusion: Trastuzumab is an important agent for the treatment of HER2-overexpressing gastric cancer. We recorded an acceptable safety and efficacy profile in this small cohort treated with anthracycline-based chemotherapy with trastuzumab followed by trastuzumab maintenance.",
keywords = "Chemotherapy, Gastric cancer, Trastuzumab",
author = "Sofia Palacio and Arturo Loaiza-Bonilla and Muaiad Kittaneh and Christos Kyriakopoulos and Ochoa, {Roberto E.} and Mauricio Escobar and Belisario Arango and Restrepo, {Maria H} and Merchan, {Jaime R} and Lima, {Caio M S Rocha} and Peter Hosein",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "301--306",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer

AU - Palacio, Sofia

AU - Loaiza-Bonilla, Arturo

AU - Kittaneh, Muaiad

AU - Kyriakopoulos, Christos

AU - Ochoa, Roberto E.

AU - Escobar, Mauricio

AU - Arango, Belisario

AU - Restrepo, Maria H

AU - Merchan, Jaime R

AU - Lima, Caio M S Rocha

AU - Hosein, Peter

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: There is no standard chemotherapy regimen that is universally accepted for the treatment of advanced gastric cancer. Trastuzumab added to chemotherapy improves survival in patients with metastatic human epidermal growth factor receptor-2 (Her2/neu)-overexpressing gastric cancer. Data are lacking for the combination of trastuzumab with other chemotherapy regimens, apart from the cisplatin/fluorouracil backbone used in the pivotal TOGA trial. Patients and Methods: In this retrospective analysis, we included patients with gastric cancer with HER2 overexpression who received trastuzumab in addition to their first-line chemotherapy, with or without trastuzumab maintenance therapy. The end-points were response and tolerance to treatment. Results: We identified seven patients who met the search criteria; six had metastatic disease and one had locally advanced unresectable disease. Four patients received epirubicin/oxaliplatin/capecitabine/trastuzumab, and the others had non-anthracycline-based chemotherapy with trastuzumab. All patients had radiological responses to treatment - one had a complete response and six had partial responses. Among the four patients who received anthracycline-based chemotherapy with trastuzumab, there was a transient decline in cardiac ejection fraction in three, but all resolved without sequelae. All patients received a period of chemotherapy induction followed by trastuzumab monotherapy for maintenance. The median progression-free survival was 14.6 months and median overall survival was 16.4 months. Conclusion: Trastuzumab is an important agent for the treatment of HER2-overexpressing gastric cancer. We recorded an acceptable safety and efficacy profile in this small cohort treated with anthracycline-based chemotherapy with trastuzumab followed by trastuzumab maintenance.

AB - Background: There is no standard chemotherapy regimen that is universally accepted for the treatment of advanced gastric cancer. Trastuzumab added to chemotherapy improves survival in patients with metastatic human epidermal growth factor receptor-2 (Her2/neu)-overexpressing gastric cancer. Data are lacking for the combination of trastuzumab with other chemotherapy regimens, apart from the cisplatin/fluorouracil backbone used in the pivotal TOGA trial. Patients and Methods: In this retrospective analysis, we included patients with gastric cancer with HER2 overexpression who received trastuzumab in addition to their first-line chemotherapy, with or without trastuzumab maintenance therapy. The end-points were response and tolerance to treatment. Results: We identified seven patients who met the search criteria; six had metastatic disease and one had locally advanced unresectable disease. Four patients received epirubicin/oxaliplatin/capecitabine/trastuzumab, and the others had non-anthracycline-based chemotherapy with trastuzumab. All patients had radiological responses to treatment - one had a complete response and six had partial responses. Among the four patients who received anthracycline-based chemotherapy with trastuzumab, there was a transient decline in cardiac ejection fraction in three, but all resolved without sequelae. All patients received a period of chemotherapy induction followed by trastuzumab monotherapy for maintenance. The median progression-free survival was 14.6 months and median overall survival was 16.4 months. Conclusion: Trastuzumab is an important agent for the treatment of HER2-overexpressing gastric cancer. We recorded an acceptable safety and efficacy profile in this small cohort treated with anthracycline-based chemotherapy with trastuzumab followed by trastuzumab maintenance.

KW - Chemotherapy

KW - Gastric cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84897022909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897022909&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 301

EP - 306

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -